Product Overview

AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases. 

Neurology & Metabolic Disorders

Adasuve®

is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder. 

Drug Facts
Active Ingredient
Loxapine
Neurology & Metabolic Disorders

Adepend® Dependex®

Adepend is used as part of a comprehensive treatment programme against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.

Drug Facts
Active Ingredient
Naltrexone
Cardiology & Pulmonology

Ambrisentan AOP

is used to treat pulmonary arterial hypertension in adults.

Drug Facts
Active Ingredient
Ambrisentant
HematoOncology

Anagrelide AOP

Anagrelide AOP is indicated in Essential Thrombocythemia for the reduction of elevated platelet counts and associated clinical symptoms in at high risk patients

Drug Facts
Active Ingredient
Anagrelide
Intensive Care

Argipressin AOP

Argipressin AOP is used to treat diabetes insipidus and bleeding from enlarged veins in the oesophagus.

Drug Facts
Active Ingredient
Argipressin
HematoOncology

BESREMi®

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

Drug Facts
Active Ingredient
Ropeginterferon alfa-2b
HematoOncology

Canemes®

Canemes® is indicated for the treatment of nauseas and vomiting in adults who do not adequately respond to other anti-emetic treatment options.

Drug Facts
Active Ingredient
Nabilone
Neurology & Metabolic Disorders

Dependex®

Drug Facts
Active Ingredient
Intensive Care

Empressin®

Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.

Drug Facts
Active Ingredient
Agripressin
Intensive Care

Esmocard® Lyo Esmolol Amomed

Esmolol hydrochloride is indicated for supraventricular tachycardia (except for pre-excitation syndromes) and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated for tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician’s judgement the rapid heart rate requires specific intervention.

Drug Facts
Active Ingredient
Esmolol
Neurology & Metabolic Disorders

Motetis

Motetis is used as symptomatic therapy in the treatment of Huntington’s disease.

Drug Facts
Active Ingredient
Tetrabenazine
Intensive Care

Nalpain®

is prescribed for short-term relief of moderate to severe pain e.g. post-surgery, in labour pain and gynecology, in myocardial infarction. Antagonizing an opioid induced respiratory depression, e.g. following fentanyl-combined narcosis. use in a combined narcosis ."

Drug Facts
Active Ingredient
Nalbuphine
Intensive Care

Nalpuphin Amomed®

Drug Facts
Active Ingredient
Intensive Care

Nexodal

Complete or partial reversal of CNS depressive effects, especially respiratory depression, caused by natural or synthetic opioids and partial agonist/antagonist opioids. It is also used to diagnose a suspected acute opioid overdose or intoxication or to reduce the effect of opioids, which were used for anesthesia in operations.

Drug Facts
Active Ingredient
Naloxone
Intensive Care

Noradrenalin Orpha

Drug Facts
Active Ingredient
Argipressin
Neurology & Metabolic Disorders

Ocaliva®

Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

Drug Facts
Active Ingredient
Obeticholic acid